Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG)
Gastric Cancer Feb 14, 2018
Jung M, et al. - This research was designed to assess the efficacy and safety of ramucirumab outside of a clinical trial using an expanded access program (EAP). Ramucirumab showed similar efficacy as seen in the results of previous trials for gastric cancer in the Korean EAP cohort. However, in the ramucirumab plus paclitaxel group, the level of gastrointestinal (GI) perforation was slightly increased.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
